Where biotech breakthroughs meet investment

Join Europe’s leading CGT investment community for exclusive access to the startups, scaleups, and scientists redefining advanced therapies. At Advanced Therapies Europe 2025, investors gain curated visibility, strategic insight, and unmatched deal-making potential — all in one place.

  • Meet pre-vetted biotech founders through 1:1 partnering
  • Join the Investor Summit for peer-to-peer networking and market insight
  • Scout pre-Series B companies pitching live at the Innovation Exchange
  • Stay ahead with data-driven discussions on trends, timelines, and ROI
  • Participate as a judge, moderator, or thought leader

Secure Your Free Investor Pass

 

Meet the Investor Summit speakers

Key themes and sessions to discover

  • Access curated discussions on market trends, valuation shifts, and risk frameworks and enable sharper decision-making and deal selection.

  • See pre-vetted companies present their value proposition in real-time and efficiently scan pipeline potential and find hidden gems.

  • Learn which CGT business models are surviving current market pressures to better identify who will deliver ROI.

  • Pre-schedule meetings with founders and fellow VCs to accelerate diligence and fosters co-investment opportunities.

Must attend sessions

  • Panel: Bridging the funding gap – How to get from pre-clinical to clinical without stalling out

  • Panel: The reality of raising funds for CGT startups

  • Innovation Exchange (startups pitch to investors)

  • Panel: The state of the CGT industry & turning the future into action

  • Roundtables: Investor expectations: what do you need for each funding stage?

Investment Summit Agenda

Loading
09:30
  1. Registration & networking
    Partnering room
    30 mins
    • Investment Summit
    Registration
10:00
  1. Partnering room
    10 mins
    • Investment Summit

    A VC leader or industry analyst to set the tone, covering the investment climate for advanced therapies, emerging hotspots and why early-stage innovation is still worth investing in

10:15
  1. Partnering room
    40 mins
    • Investment Summit

    Bringing together investors across the funding spectrum (from seed-stage VCs to growth investors) to share what drives decision making in today’s market

11:00
  1. Partnering room
    25 mins
    • Investment Summit

    A showcase from 2 early-stage biotech’s outlining not just what they want from funding partners but what they need – mentorship, guidance, expertise and access to networks

11:30
  1. Partnering room
    20 mins
    • Investment Summit

    A candid conversation between a biotech founder and their early investor exploring the startup journey

11:50
  1. Refreshment & networking break
    Partnering room
    10 mins
    • Investment Summit
    1-2-1 Meetings
12:25
  1. Partnering room
    25 mins
    • Investment Summit

    A rapid-fire panel / multi-perspective session on high-growth areas in biotech. Each speaker gives a 5-minute outlook on where their focus and how this aligns with market trends

13:00
  1. Partnering room
    5 mins
    • Investment Summit
    Wrap up from senior VC – covering the landscape of what’s next and where biotech investment will grow for the next 5 years
13:05
  1. Investment Summit & Women In Advanced Therapies Lunch
    Partnering room
    55 mins
    • Investment Summit
    • Women in Advanced Therapies
    Lunch break and networking

Discover Advanced Therapies Week as an investor

Explore how Advanced Therapies Week empowers biotechs to accelerate their commercialization journey. From engaging with investors at our exclusive Investor Pre-Day to building valuable partnerships with industry leaders, every moment is designed to drive your success. Dive into the agenda, connect with peers, and meet solution providers ready to support your growth.

Content Packed Agenda

Start with macro and micro trends shaping CGT investment — from capital flows to platform-based valuations.

Founders in Focus

Biotech CEOs share real-world experiences in securing funding, navigating milestones, and scaling in complex markets.

Investor Sessions

Get behind-the-scenes access to the thinking of investors from firms like BroadOak Capital Partners, 4BIO Capital, and Saisei Ventures.

Strategic Networking

1:1 meetings and informal conversations with decision-makers continue throughout ATE — the summit is your introduction.

Who might you find on the show floor?

Sample Attendee List Current Exhibitor List

500+
Attendees
40+
Countries
150+
Speakers
170+
Therapeutic Developers

 

  • “I get SO MUCH information at this show that sets me up for the year. It’s what I love about it. To me, ATW is the start of the year.”
    Principal, WMC
  • “The Super Bowl of Advanced Cell Therapy conferences.”
    Patient & Author, Killing Cancer with TILs
  • "Everyone that has a word to say, or a finger on the lifecycle of a cell therapy product should come here…”
    President & CEO, Co-founder, NKILT Therapeutics Inc.
  • “Advanced Therapies Week has been the epicenter of the cell & gene therapy revolution. This is a dynamic and must-attend forum where breakthrough technologies and impactful partnerships come to life to transform drug development.”
    Bullpen
09:55
  1. Plenary

    Deep dive into the regulatory framework that governs CGT across major rejoins, focusing on recent updates, new legislation and how companies can navigate the changing landscape.

10:25
  1. Plenary
    A conversation with key patient advocates and organisations to highlight the importance of patient engagement, access, and ensuring therapies meet real-world needs in CGT.
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Cutting edge developments in CRISPR, gene editing and cell engineering
    • The next wave of in vivo and ex vivo gene therapies
    • What breakthroughs are expected to reshape the industry?
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • As the pressure mounts to deliver advanced therapies faster, cheaper, and closer to the patient, decentralised manufacturing is stepping into the spotlight. But does breaking away from centralised models really deliver on cost? 

    • This panel dives into the economic realities behind the decentralisation trend. Are localised manufacturing hubs the answer to cutting costs, or do they introduce new layers of complexity and hidden spend? From infrastructure investments to regulatory headaches, we’ll separate financial fact from fiction and explore whether decentralisation is a bold leap forward or an expensive detour. 

12:25
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
12:50
    • R&D, clinical innovation & translation
    Theatre 1
    • Scientific advances and key breakthroughs.
    • Safety, efficacy, and regulatory challenges.
    • Investment trends and commercialisation potential.
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Balancing technical and financial realities in manufacturing
    • When to invest in infrastructure vs outsourcing
    • The role of automation in optimising CMC process
14:30
    • R&D, clinical innovation & translation
    Theatre 1
    • How startups secure investment before reaching human trials 

    • strategic and tactical guidance on how to secure the right funding at the right time, from seed rounds through Series A 

    • Investor insights into due diligence, risk mitigation and valuation and what good really looks like  

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Transitioning from academic proof of concept to market-ready product 

    • Why biotech teams must integrate CMC, regulatory and pharmacology early 

    • Avoiding pitfalls of overselling and overpromising 

15:05
    • R&D, clinical innovation & translation
    Theatre 1
    • Why characterisation and analytics remain a major hurdle. 

    • Collaborative approaches to tackling technical challenges 

    • Best practices and emerging solutions. 

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    Discuss the key challenges in patient-centric manufacturing, focusing on ensuring timely delivery of therapies, managing logistics, and addressing issues related to personalised treatments, from patient selection to product delivery. 
15:40
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
16:00
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
11:50
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
12:15
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Explore strategies for securing reimbursement and market access for cell and gene therapies, focusing on pricing, HTAs, and policy advocacy to ensure patient access. 

14:00
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
14:20
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
15:15
  1. Plenary

    AI is everywhere, but in CGT, real deployment remains limited. This session goes beyond the buzz to explore the tangible opportunities, early wins, and critical barriers to broader adoption. 

    We’ll look at where AI is beginning to make a difference and what’s still needed to move from isolated pilots to real impact. What kind of data, infrastructure, and cross-functional collaboration will unlock AI’s full potential in CGT? 

16:00
  1. Plenary
    As we wrap up two days of deep discussions on the current state of the European CGT landscape, this final panel will chart the path ahead. Which steps must Europe take to remain competitive and lead the way in the next 5–10 years? Each panellist will share their key takeaways from the last two days, reflecting on the insights, challenges, and opportunities discussed.